New drug cocktail aims to shrink tough head and neck tumors

NCT ID NCT06062420

Ongoing Disease control Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests whether combining newer immunotherapy drugs (belrestotug, nelistotug, remzistotug) with the standard drug dostarlimab can shrink tumors better than dostarlimab alone in people with advanced head and neck cancer that has come back or spread. About 316 participants whose cancer has a specific protein (PD-L1) will receive one of the combinations or the standard drug. The main goal is to see how many people's tumors shrink significantly.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Dostarlimab, Belrestotug, Nelistotug, Remzistotug (immunotherapy drugs)

What this could lead to

If successful, this could point toward more effective first-line treatment options for people with advanced head and neck cancer, potentially shrinking tumors better than current immunotherapy alone.

What could go wrong

This is a mid-stage trial with only 316 participants, so results may not apply to everyone. Immunotherapy can cause serious side effects like inflammation of organs, and the new combinations might not work better than the standard drug.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

head and neck neoplasm Head and Neck Neoplasms head and neck squamous cell carcinoma Squamous Cell Carcinoma of Head and Neck

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEOPLASMS, HEAD AND NECK

Contacts and locations

Show contact details

Locations

GSK Investigational Site

New Haven, Connecticut, 06511, United States
GSK Investigational Site

Iowa City, Iowa, 52242, United States
GSK Investigational Site

St Louis, Missouri, 63021, United States
GSK Investigational Site

Columbus, Ohio, 43210, United States
GSK Investigational Site

Milwaukee, Wisconsin, 53226, United States
GSK Investigational Site

Buenos Aires, C1426ABP, Argentina
GSK Investigational Site

Capital Federal, C1181ACH, Argentina
GSK Investigational Site

Ciudad Autonoma de Bueno, C1056ABI, Argentina
GSK Investigational Site

Córdoba, 5000, Argentina
GSK Investigational Site

Florida, B1602DQD, Argentina
GSK Investigational Site

Mendoza, M5500AYB, Argentina
GSK Investigational Site

San Juan, 5400, Argentina
GSK Investigational Site

Santa Fe, 3000, Argentina
GSK Investigational Site

Santo André, 09060-650, Brazil
GSK Investigational Site

São Paulo, 01221-020, Brazil
GSK Investigational Site

São Paulo, 01246-000, Brazil
GSK Investigational Site

Calgary, Alberta, T2N 5G2, Canada
GSK Investigational Site

Edmonton, Alberta, T6G 1Z2, Canada
GSK Investigational Site

Toronto, Ontario, M4N 3M5, Canada
GSK Investigational Site

Toronto, Ontario, M5G 2M9, Canada
GSK Investigational Site

Montreal, Quebec, H3T 1E2, Canada
GSK Investigational Site

Herlev, Denmark
GSK Investigational Site

Turku, 20520, Finland
GSK Investigational Site

Bordeaux, 33075, France
GSK Investigational Site

Caen, 14075, France
GSK Investigational Site

Marseille, 13005, France
GSK Investigational Site

Paris, 75005, France
GSK Investigational Site

Rouen, 76038, France
GSK Investigational Site

Villejuif, 94805, France
GSK Investigational Site

Aachen, 52074, Germany
GSK Investigational Site

Berlin, 12200, Germany
GSK Investigational Site

Essen, 45122, Germany
GSK Investigational Site

Frankfurt, 60488, Germany
GSK Investigational Site

Giessen, 35392, Germany
GSK Investigational Site

Hamburg, 20246, Germany
GSK Investigational Site

Regensburg, 93053, Germany
GSK Investigational Site

Ulm, 89075, Germany
GSK Investigational Site

Haidari - Athens, 12462, Greece
GSK Investigational Site

Marousi, Greece
GSK Investigational Site

Thessaloniki, 55236, Greece
GSK Investigational Site

Győr, 9024, Hungary
GSK Investigational Site

Kecskemét, 6000, Hungary
GSK Investigational Site

Pécs, 7624, Hungary
GSK Investigational Site

Bari, 70124, Italy
GSK Investigational Site

Bologna, 40139, Italy
GSK Investigational Site

Florence, 50134, Italy
GSK Investigational Site

Genova, 16132, Italy
GSK Investigational Site

Milan, 20133, Italy
GSK Investigational Site

Naples, 80131, Italy
GSK Investigational Site

Novara, 28100, Italy
GSK Investigational Site

Padova, 35128, Italy
GSK Investigational Site

Roma, 00144, Italy
GSK Investigational Site

Roma, 00168, Italy
GSK Investigational Site

Rozzano MI, 20089, Italy
GSK Investigational Site

Aichi, 464-8681, Japan
GSK Investigational Site

Chiba, 277-8577, Japan
GSK Investigational Site

Hyōgo, 650-0017, Japan
GSK Investigational Site

Osaka, 541-8567, Japan
GSK Investigational Site

Saitama, 350-1298, Japan
GSK Investigational Site

Shizuoka, 411-8777, Japan
GSK Investigational Site

Tokyo, 104-0045, Japan
GSK Investigational Site

Oslo, 0379, Norway
GSK Investigational Site

Bielsko-Biala, 43-300, Poland
GSK Investigational Site

Katowice, 40-514, Poland
GSK Investigational Site

Krakow, 31-826, Poland
GSK Investigational Site

Przemyśl, 37-700, Poland
GSK Investigational Site

Siedlce, 08-110, Poland
GSK Investigational Site

Warsaw, 04-141, Poland
GSK Investigational Site

Almada, 2801-951, Portugal
GSK Investigational Site

Lisbon, 1649-035, Portugal
GSK Investigational Site

Porto, 4099-001, Portugal
GSK Investigational Site

Porto, 4200-072, Portugal
GSK Investigational Site

Brasov, 500283, Romania
GSK Investigational Site

Bucharest, 020142, Romania
GSK Investigational Site

Bucharest, 022328, Romania
GSK Investigational Site

Bucharest, 030171, Romania
GSK Investigational Site

Bucharest, 30463, Romania
GSK Investigational Site

Craiova, 200542, Romania
GSK Investigational Site

Floreşti, 407280, Romania
GSK Investigational Site

Iași, 700483, Romania
GSK Investigational Site

Oradea, 410469, Romania
GSK Investigational Site

Piteşti, 110283, Romania
GSK Investigational Site

Suceava, 720214, Romania
GSK Investigational Site

Daegu, 42601, South Korea
GSK Investigational Site

Seongnam-si Gyeonggi-do, 13620, South Korea
GSK Investigational Site

Seoul, 03722, South Korea
GSK Investigational Site

Seoul, 138-736, South Korea
GSK Investigational Site

Suwon Kyunggi-do, 443-721, South Korea
GSK Investigational Site

Barcelona, 08023, Spain
GSK Investigational Site

Barcelona, 08035, Spain
GSK Investigational Site

Barcelona, 08907, Spain
GSK Investigational Site

Jaén, 23007, Spain
GSK Investigational Site

Madrid, 28010, Spain
GSK Investigational Site

Madrid, 28034, Spain
GSK Investigational Site

Madrid, 28040, Spain
GSK Investigational Site

Madrid, 28041, Spain
GSK Investigational Site

Pozuelo de AlarcOn Madr, 28223, Spain
GSK Investigational Site

Salamanca, 37007, Spain
GSK Investigational Site

Santander, 39008, Spain
GSK Investigational Site

Valencia, 46009, Spain
GSK Investigational Site

Zaragoza, 50009, Spain
GSK Investigational Site

Changhua, 500, Taiwan
GSK Investigational Site

Tainan, 704, Taiwan
GSK Investigational Site

Taipei, 10002, Taiwan
GSK Investigational Site

Taipei, 11217, Taiwan
GSK Investigational Site

Ankara, 06100, Turkey (Türkiye)
GSK Investigational Site

Istanbul, 34662, Turkey (Türkiye)
GSK Investigational Site

Izmir, 35040, Turkey (Türkiye)